One of the patents is related to the treatment of a wide range of autoimmune and inflammatory diseases such as multiple sclerosis, arthritis and psoriasis. The patent was filed based on considerable evidence that the pathway, involving the SDF-1 chemokine and its CXCR4 receptor, plays a significant role in autoimmune diseases.
The other patent is related to the use of chemokine SDF-1 to induce blood vessel growth to treat cardiovascular, peripheral vascular and other vascular diseases. This chemokine also has the potential for activity in tissue injuries such as wound healing.
Donald Wong, vice president of drug development at Chemokine, said: “These patents help strengthen the company’s growing proprietary position in chemokine-based therapies which seek to address unmet medical needs.”